FDA Approves Moderna's New Lower-Dose COVID-19 Vaccine
The FDA has approved Moderna’s new lower-dose COVID-19 vaccine, mNexspike, offering tailored protection for high-risk populations. Learn more about this innovative development in COVID-19 immunization.
The U.S. Food and Drug Administration (FDA) has officially authorized a new, lower-dose version of Moderna's COVID-19 vaccine, designed to enhance protection in high-risk populations. This innovative vaccine, known as mNexspike, is a significant advancement in coronavirus immunization technology. It features a dose that is approximately one-fifth of the standard amount used in Moderna's Spikevax, achieved through a targeted design that aims to provoke a more focused immune response. Importantly, this new vaccine is not intended to replace the existing Moderna COVID-19 shot but rather to serve as an additional option.
mNexspike is approved specifically for individuals aged 65 and older who have been previously vaccinated with any COVID-19 vaccine, as well as for those aged 12 to 64 who possess at least one underlying health condition that increases their risk of severe illness from COVID-19. This limited authorization aligns with the approval of other targeted vaccines like Novavax's last month.
In the upcoming fall, Moderna plans to offer both Spikevax and mNexspike, providing flexibility in COVID-19 vaccination strategies. The current primary vaccine remains widely accessible for individuals aged 6 months and older without restrictions.
Moderna’s CEO, Stephane Bancel, emphasized that the new lower-dose vaccine is a valuable addition to the arsenal of tools available to protect high-risk groups against severe COVID-19 outcomes. The approval marks an important step in refining vaccine strategies to better address the ongoing pandemic.
For more details, visit source.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Waist-to-Height Ratio as a Key Predictor of Heart Failure Risk
A new study indicates that waist-to-height ratio is a strong predictor of incident heart failure, surpassing traditional measures like BMI. This metric helps identify at-risk individuals based on fat distribution around visceral organs.
Innovative Multilingual AI Chatbot Enhances Emergency Department Triage for Bilingual Patients
Researchers at UNSW are developing a multilingual AI chatbot to improve emergency department triage accuracy for bilingual patients, addressing language and cultural barriers in urgent healthcare settings.
Decoding Sentence Construction in the Brain: Insights from Electrocorticography Research
New research using electrocorticography reveals how the brain assembles sentences, highlighting the roles of different brain regions in sequencing and syntax during speech production.
Study Reveals How COVID-19 Reprograms White Blood Cells to Suppress the Immune Response
New research reveals how SARS-CoV-2 reprograms neutrophils into immune-suppressing cells, contributing to severe COVID-19 by weakening the body's defense mechanisms. Learn about potential therapeutic targets.